Since the emergence of the COVID-19 pandemic, there has been increased interest in developing a universal antiviral that would stop a pandemic in its tracks.


Britain’s GSK halted enrollment and vaccination in three trials of the company’s experimental vaccine against the respiratory syncytial virus (RSV) in pregnant women, the latest setback in developing a vaccine for the microbe.

Pneumonia killed more than 800,000 babies and young children during 2018 – or one child every 39 seconds – despite being curable and mostly preventable, global health agencies said.